Novel angiotensin I-converting enzyme inhibitory peptide derived from bovine casein

• Published in: Food chemistry Vol. 141; no. 4; pp. 3781 - 3789
• Main Authors: Yamada, Akio, Sakurai, Takuma, Ochi, Daisuke, Mitsuyama, Eri, Yamauchi, Koji, Abe, Fumiaki
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 15.12.2013; Elsevier
• Subjects: Administration, Oral; Angiotensin I-converting enzyme; Angiotensin-Converting Enzyme Inhibitors - chemistry; Angiotensin-Converting Enzyme Inhibitors - isolation & purification; Animals; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - chemistry; Biological and medical sciences; Blood Pressure - drug effects; Casein; Caseins - chemistry; Cattle; Food toxicology; Humans; Hydrolysate; Hypertension - drug therapy; Hypertension - physiopathology; Male; Medical sciences; Met-Lys-Pro; MKP; Peptides - administration & dosage; Peptides - chemistry; Peptidyl-Dipeptidase A - analysis; Protein Hydrolysates - chemistry; Rats; Rats, Inbred SHR; Toxicology; Angiotensin I-converting enzyme; MKP; Casein; Hydrolysate; Met-Lys-Pro; Bovine; Peptides; Ox; Milk protein; Vertebrata; Mammalia; Animal; Artiodactyla; Ungulata; EC 3.4.15.1
• ISSN: 0308-8146; 1873-7072
• DOI: 10.1016/j.foodchem.2013.06.089

•We hydrolysed bovine casein by combination of subtilisin, bacillolysin, and trypsin.•The hydrolysate (CH-3) had a strong ACE inhibitory activity in vitro.•The CH-3 lowered the blood pressure of spontaneously hypertensive rats.•We analysed CH-3 and found the novel ACE inhibitory peptide (Met-Lys-Pro).•The Met-Lys-Pro lowered the blood pressure of spontaneously hypertensive rats. Bovine lactic casein was hydrolysed using a combination of three enzymes, namely, subtilisin, bacillolysin, and trypsin, and the resulting preparation was coined CH-3. CH-3 showed angiotensin I-converting enzyme (ACE)-inhibitory activity (IC50: 74μg/mL). A single oral administration of CH-3 led to a transient but significant decrease in the systolic blood pressure (SBP) of spontaneously hypertensive rats (SHRs), while daily oral administration of CH-3 for 28 consecutive days led to a lower rate of SBP increase. The CH-3 preparation was then fractionated and the αS2-casein-derived tripeptide Met-Lys-Pro (or MKP) was identified as a novel peptide with strong ACE-inhibitory activity (IC50=0.12μg/mL, 0.3μM). The MKP peptide constituted only 0.053% of CH-3 but its activity was accounted for 33% of the total ACE-inhibitory activity of CH-3. In addition, a single oral administration of MKP also led to a transient but significant decrease in the SBP of SHRs.